This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition.
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network
Cattalini, Marco;
2021-01-01
Abstract
This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
R92Q_AIDA.pdf
accesso aperto
Tipologia:
Full Text
Licenza:
PUBBLICO - Creative Commons 4.0
Dimensione
340.98 kB
Formato
Adobe PDF
|
340.98 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
